AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 21 min read$VSTM

Paterson Dan sold $353K of VSTM

Paterson Dan (President and CEO) sold 44,121 shares of Verastem, Inc. (VSTM) at $8.00 ($0.35M total) on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Oct 2, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Bearish
medium confidence
Mentioned
$VSTM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMBearishLow
01

Why it matters

Provides fresh, primary‑source data on insider activity, useful for short‑term risk assessment.

02

Market read

Insider sale is a modest but material event for VSTM shareholders; limited broader market relevance.

03

What to watch

Potential upcoming clinical data releases may offset short‑term sell pressure.

Relevance 3/10Novelty 3/10Timing: today

Background

SEC Form 4 filing discloses an insider transaction by Verastem's CEO.

Company-level read

Ticker impact

$VSTMBearishMedium confidence
Context

Form 4 filing shows CEO sold 44,121 shares for $352,968, a direct insider sale via 10b5-1 plan.

Expected impact

likely slight pressure as the market prices in the insider sale

Evidence & confidence

Sale size is modest but involves the CEO; such transactions often prompt short-term selling pressure.

Market effects

Sector

Minimal impact on the biotech sector; insider sales are company‑specific.

Regional

No broader regional effect.

Global

Limited to investors tracking VSTM.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to fundamentals.

Key entities

  • company
    Verastem, Inc.

    Biotech firm listed on NASDAQ under ticker VSTM.

  • person
    Paterson Dan

    President and CEO of Verastem, filing the insider sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

OCT 5
$VSTMMedAI 8/10

Verastem shares get Buy rating reiterated by H.C. Wainwright

H.C. Wainwright reiterated a Buy rating on Verastem (VSTM) with a $18.00 price target, citing positive clinical data for avutometinib plus defactinib in ovarian cancer. The stock trades at $7.70, with a Strong Buy consensus. Verastem reported a narrower-than-expected Q2 2026 loss and revenue exceeding forecasts, driven by product sales and a license payment. Cantor Fitzgerald also reiterated an Overweight rating.

investing.com2 min
OCT 2
$VSTMHighAI 9/10

Verastem presents new data on ovarian cancer drug combination

Verastem Oncology presented data from its Phase 2 RAMP 201 trial, showing positive results for its drug combination in treating recurrent low-grade serous ovarian cancer. The combination achieved objective response rates of 22% and 18% in specific patient groups, with median progression-free survival of 13 months. The FDA approved the combination in May 2025, pending confirmatory trial results. The data was presented at the International Gynecologic Cancer Society Annual Global Meeting.

investing.com2 min
AUG 20
$VSTMHighAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

aol.com3 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min